본문으로 건너뛰기
← 뒤로

SLC7A11-specific CAR-T cell therapy potently targets colorectal and pancreatic cancer.

1/5 보강
iScience 📖 저널 OA 100% 2023: 4/4 OA 2024: 21/21 OA 2025: 69/69 OA 2026: 112/112 OA 2023~2026 2025 Vol.28(11) p. 113713
Retraction 확인
출처

Pan X, Li J, Zhu J, Wang X, Liu Y, Tian X, Yang Y, Wang P, Chen S

📝 환자 설명용 한 줄

SLC7A11 is highly expressed in various solid tumors, including colorectal cancer and pancreatic cancer.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Pan X, Li J, et al. (2025). SLC7A11-specific CAR-T cell therapy potently targets colorectal and pancreatic cancer.. iScience, 28(11), 113713. https://doi.org/10.1016/j.isci.2025.113713
MLA Pan X, et al.. "SLC7A11-specific CAR-T cell therapy potently targets colorectal and pancreatic cancer.." iScience, vol. 28, no. 11, 2025, pp. 113713.
PMID 41189595 ↗

Abstract

SLC7A11 is highly expressed in various solid tumors, including colorectal cancer and pancreatic cancer. The aim of the study was to report the therapeutic potential of SLC7A11 CAR-T therapy. The SLC7A11-specific antibodies were generated by hybridoma and humanization technologies. The cytotoxicity was validated through co-culture assays of effector cells with cancer cell lines. The anti-tumor studies were evaluated by cell line-derived xenograft (CDX) and patient-derived xenograft (PDX) models. We first confirmed the tumor specificity of SLC7A11 and then successfully developed SLC7A11-specific CAR-T cells. CCK-8 and LDH cytotoxicity assays demonstrated that cancer cells co-cultured with CAR-T cells exhibited higher mortality rates. Animal experiments showed that SLC7A11 CAR-T treatment suppressed the tumor growth without causing significant abnormalities in blood biochemical parameters. In conclusion, SLC7A11 CAR-T cell therapy showed remarkable anti-tumor capabilities and safety in colorectal and pancreatic cancer.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

같은 제1저자의 인용 많은 논문 (5)

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반

🟢 PMC 전문 열기